Biome Australia Limited (BIO.XA) Stock Research Report

1. Executive Summary:

Biome Australia Limited (ASX: BIO) is a microbiome health company specializing in evidence-based probiotics and complementary medicines. Founded in 2018 and based in Australia, Biome develops and markets innovative live biotherapeutic products under its flagship Activated Probiotics brandcanarycapital.com.aucanarycapital.com.au. These proprietary probiotic formulations, supported by clinical research, target various health concerns (e.g. mood, sleep, bone health, iron absorption, gut disorders) via the gut microbiomecanarycapital.com.au. The company primarily sells through Australian community pharmacies and health practitioners, with the pharmacy channel contributing about two-thirds of revenue (same-store pharmacy sales grew ~75% in FY2024)canarycapital.com.au. Biome is expanding internationally, with initial distribution in the UK and a recent launch into Canada, and also offers an organic nutraceutical range (Activated Nutrients) as part of its product portfoliocanarycapital.com.aucanarycapital.com.au. In summary, Biome Australia is an emerging player in the consumer health sector, focused on probiotic-based therapeutics and related wellness products.

2. Business Drivers & Strategic Overview:

Revenue Drivers: Biome’s growth is driven primarily by its Activated Probiotics product line and expanding distribution network. A key driver is the company’s focus on pharmacy and practitioner channels, where it provides extensive education to health professionals, resulting in strong product recommendation and sell-through. In fact, Activated Probiotics has become Australia’s highest-growth complementary medicine brand, with community pharmacies reporting same-store sales growth of 75%canarycapital.com.au. The pharmacy channel (including major chains like Priceline and Terry White Chemmart) is Biome’s largest revenue source, while a practitioner-only channel and direct e-commerce contribute additional sales. High repeat purchase rates (given chronic health uses) and new product launches further underpin revenue quality.

Growth Initiatives: Biome has pursued aggressive growth initiatives. Domestically, it expanded distribution points by 20% in H1 FY2025 to reach ~6,000 outlets nationwidecanarycapital.com.au, moving toward a goal of 8,000 by 2027canarycapital.com.au. Internationally, the company entered North America and Europe – launching in Canada in late 2024 through a partnership with distributor Ecotrend Ecologicscanarycapital.com.au, and building presence in the UK and other markets. Early traction abroad has been positive, and international sales nearly doubled in FY2024 (to ~$0.9M)canarycapital.com.au. Biome’s product development pipeline is another growth vector: during FY2024 the company introduced several new probiotic products (e.g. Biome Cholesterol™ aimed at healthy cholesterol management) and commenced development of its own proprietary probiotic strain BMB18canarycapital.com.au. This R&D initiative, supported by a government grant (via FaBA partnership), is expected to yield unique patented strains to fuel future products and strengthen Biome’s competitive moatcanarycapital.com.aucanarycapital.com.au. Furthermore, Biome plans to launch a new “Activated Therapeutics” range in H2 FY2025, expanding beyond probiotics into adjacent gut health categoriescanarycapital.com.au.

Competitive Advantages: Biome’s strategy centers on evidence-based, high-efficacy products and education-led sales, which differentiates it from many supplement rivals. Its partnerships with leading microbiome research organizations and use of clinical trials lend scientific credibility to the Activated Probiotics rangecanarycapital.com.au. The products are shelf-stable (no refrigeration) with long shelf lives, ideal for broad distributioncanarycapital.com.au. Biome has also secured intellectual property – e.g. proprietary probiotic strains (like BMB18) and novel delivery technologies – which can provide protection from competitorscanarycapital.com.au. Additionally, the company’s growing pharmacy relationships and recent award as Retail Supplier of the Year by Terry White Chemmart (Australia’s largest pharmacy chain) demonstrate a strong market reputation and entrenched channel presenceinvestorpa.com. Overall, Biome’s growth strategy leverages its unique product innovations, expanding distribution footprint, and credibility with health professionals to drive sales momentum.

3. Financial Performance & Valuation:

Recent Performance (FY2024–FY2025): Biome has delivered robust financial growth. In FY2024 (year ended June 30, 2024), sales revenue reached A$13.01 million, up 80% from FY2023canarycapital.com.au. This surge was fueled by both domestic demand and overseas expansion (international sales grew 95% to ~$0.9M)canarycapital.com.au. Gross profit was ~$7.9M, with gross margins improving to over 60% (from ~59% in FY2023)canarycapital.com.au, reflecting premium pricing and scale benefits. While Biome recorded a net loss of ~A$1.7M for FY2024 (narrowed from a larger loss in FY2023), the trend turned positive in the first half of FY2025. For H1 FY2025 (July–Dec 2024), revenue was A$8.86M (+47% vs 1H FY2024) and the company achieved its maiden net profit of A$96k (A$433k including an R&D tax rebate)canarycapital.com.aucanarycapital.com.au. This period marked Biome’s first profitable half-year, with two quarters of positive EBITDA totaling ~$0.35M (excl. R&D and share-based costs)canarycapital.com.aucanarycapital.com.au. Ongoing quarterly updates indicate momentum continued: for example, Q3 FY2025 sales rose 41% YoY to ~$4.5M, bringing FY25 year-to-date sales to $13.4M (+46% YoY)investorpa.com. Management has stated it expects Biome’s first full-year net profit in FY2025, ahead of earlier timelines.

Key Metrics: Biome’s improving profitability is evident in its margins and cash flow. By H2 FY2024, the company was EBITDA-positive (A$287k in H2 after adjusting for non-cash costs)canarycapital.com.au and operating cash flow turned positive in the final three quarters of FY2024canarycapital.com.au. Gross margin has held around 60–61% into FY2025canarycapital.com.au, while cost control and operating leverage from higher sales are moving the bottom line toward sustained profitability. The balance sheet shows a modest cash reserve (~A$2.9M at June 30, 2024)canarycapital.com.au and no significant debt reported, with an unrecognized deferred tax asset of ~$2.7M that can shield initial profits from taxcanarycapital.com.aucanarycapital.com.au. This means Biome can reinvest cash flows into growth initiatives without near-term tax drag.

Valuation Multiples: As of mid-2025, Biome’s market capitalization is around A$100 millionintelligentinvestor.com.au, with ~219 million shares outstandingfinance.yahoo.com. At a share price of ~$0.46intelligentinvestor.com.au, the stock trades at a high trailing price-to-earnings (P/E) ratio (given only a tiny profit so far) and roughly 5–6 times FY2024 sales. On a forward basis, if Biome achieves ~A$18M revenue in FY2025 (∼40% growth) and continues its profitability trend, the forward P/S multiple would moderate to ~5x, and P/E remains elevated (in the triple-digits) until earnings scale up. Traditional valuation metrics are thus of limited use at this early earnings stage. However, Biome’s growth trajectory and guidance provide context: the company’s Vision 27 plan guides for A$75–85M in cumulative revenue over FY2025–FY2027canarycapital.com.au, implying substantial annual growth ahead. Investors seem to be pricing in strong growth (reflected in the stock’s >40% gain over the past year and a 52-week high of $0.87)finance.yahoo.com. Given Biome’s recent inflection to profitability and ongoing 40%+ revenue growth, the valuation appears to factor in optimistic expectations. Any significant execution success (or shortfall) in hitting the Vision 27 targets will likely drive a re-rating. In summary, Biome trades at growth-stock multiples (high P/S, nascent P/E), supported by its rapid revenue climb and improving margins, with the current ~A$100M market cap reflecting a bet on the company’s ability to scale into a much larger health nutrition player.

4. Risk Assessment & Macroeconomic Considerations:

Internal Risks: As a young, growing company, Biome faces execution risks. The ambitious expansion (targeting ~60% CAGR over three years) requires flawless execution in scaling operations, developing new products, and managing a larger distribution network. Any setbacks in R&D (e.g. a failure to commercialize the proprietary BMB18 strain or delays in launching the new Activated Therapeutics range) could slow growth. The company’s success is heavily tied to the Activated Probiotics line and key personnel (founder/MD Blair Norfolk is a central figure); loss of a key executive or a single product issue (e.g. a safety concern or negative study) could materially impact the brand. Biome has worked to onshore more of its supply chain and manufacturingcanarycapital.com.au, but still must manage inventory and quality carefully – any supply disruptions or cost inflation in raw materials could squeeze margins. As a small cap, liquidity and capital are considerations: while cash flows have turned positive, a major growth initiative or unforeseen cost may necessitate additional capital raise, potentially diluting shareholders if the stock price is under pressure.

External Risks: Competition in the vitamins/supplements market is intense. Biome competes with larger nutraceutical companies (both Australian and global) that have greater resources and established brands. If competitors launch similar probiotic products or aggressively discount, Biome’s growth and pricing power could be challenged. The company’s strategy of evidence-backed products is a differentiator, but it operates in a lightly regulated space – changes in regulations or classification of probiotics by the TGA could impose new requirements or barriers to market. There’s also a risk of consumer trends shifting; while gut health is currently a popular wellness focus, consumer preferences can change, and new scientific findings could alter demand for certain probiotics. Additionally, reliance on third-party distributors (for international markets) introduces partner risk – e.g. underperformance by a distributor could hinder market penetration abroad.

Macroeconomic Considerations: Broader economic trends can influence Biome’s performance. As a consumer health product company, factors like consumer spending and confidence are relevant – in economic downturns or high-inflation environments, shoppers may cut back on non-essential health supplements. Thus far, demand for Biome’s products has proven resilient, but a sustained cost-of-living squeeze could moderate growth in discretionary segments. On the other hand, structural tailwinds exist: aging populations and increasing public awareness of the microbiome’s impact on health are expanding the market for probiotics. Industry forecasts show the global probiotic supplements market growing steadily, which bodes well for Biome if it can capture share. Currency fluctuations are another consideration; Biome earns some revenue overseas and likely sources certain ingredients globally, so a strong AUD could reduce translated sales or hurt export competitiveness (and conversely, a weaker AUD could raise import costs). Lastly, market conditions affect Biome’s stock – as a small-cap growth equity, it is sensitive to shifts in investor risk appetite and interest rates. Higher interest rates can pressure high-growth stock valuations (by raising the discount rate), even if Biome’s own operations remain on track. Overall, while Biome enjoys a favorable niche in a growing market, investors should weigh the execution and competitive risks inherent to its growth story, as well as the possibility of external headwinds from economic cycles or regulatory shifts.

5. 5-Year Scenario Analysis:

We project three realistic scenarios (High, Base, Low) for Biome’s 5-year total return (in AUD, assuming no dividends). Each scenario outlines key fundamentals, potential contributions from new segments, and an expected share price in five years. A probability weight is assigned to each scenario, yielding a probability-weighted target price.

High Case (Bull): Biome exceeds growth plans and becomes a leading global probiotics player. The Activated Probiotics line achieves major international traction – for instance, successful expansion in North America and Europe yields significant revenue streams by 2030. Annual sales growth averages ~40-50% for the next few years, decelerating to ~30% by years 4–5 as the base becomes larger. By FY2030, Biome’s revenue could approach ~$60–70M/year in this scenario, with international markets and new product categories (the Activated Therapeutics range, etc.) contributing strongly. Gross margins stay ~60%+, and operating leverage improves net margins into the mid-teens. The company might also monetize non-core opportunities – e.g. licensing its proprietary strains or expanding the Activated Nutrients nutraceutical segment – adding incremental high-margin revenue. With this growth and profitability profile, Biome could command valuation multiples similar to other successful health supplement companies. We assume a P/E of ~20 in year 5 (reflecting growth still above industry average). Under these bullish assumptions, the share price 5 years out could be in the $\sim1.20 range (roughly 2.5x the current price). The table below illustrates a possible share price trajectory in this High case, reaching the target by 2030:

Key drivers: Rapid revenue growth (well above Vision 27 guidance), successful global market entry, at least one blockbuster product (e.g. cholesterol probiotic) driving category leadership, and margin expansion. In this scenario Biome might also attract interest as a takeover target by a large pharma or nutraceutical firm, potentially boosting the share price further. Probability Weight: 20%. (Summary: Bullish Breakout*)*

Base Case (Moderate): Biome delivers on its stated strategy and hits the mid-point of its Vision 27 plan. Domestic growth remains robust but naturally slows from the current 80% pace to a sustainable ~20% annual rate by later years. International expansion is moderately successful – the company secures footholds in a few markets (e.g. Canada contributes meaningfully, and one European region gains traction), but global sales are incremental rather than explosive. New product launches (like the Activated Therapeutics range) add growth, though core probiotics remain ~80% of revenue. By FY2027, Biome achieves the guided ~$80M cumulative revenue (around ~$30M in FY2027 annual sales)canarycapital.com.au, then grows in the 15–20% range for FY2028–2030. In this base scenario, FY2030 annual sales might be ~$40–45M. The company maintains solid gross margins ~60%, and achieves net profit margins around 10% as it continues investing in growth (marketing, R&D). We assume a somewhat lower valuation multiple as growth normalizes – perhaps a P/E in the mid-to-high teens by year 5. The 5-year share price in this scenario is estimated around $0.75–0.80, implying a healthy rise from current levels but not a multi-bagger. A potential price path is shown below:

Assumptions: Biome’s core business grows steadily (organically achieving ~15–20% CAGR after FY2027), with no major hiccups. The Activated Probiotics brand maintains its market position in Australia and builds a modest but growing presence overseas. Non-core segments (like nutraceuticals or licensing of IP) provide a small boost but remain <10% of revenue. Capital raises are minimal or none, as internal cash generation funds expansion. Probability Weight: 60%. (Summary: Steady Growth*)*

Low Case (Bear): Biome encounters significant challenges that stunt its growth. Competition intensifies – for instance, large supplement companies introduce rival probiotic lines that erode Biome’s pharmacy market share. Sales growth could drop sharply (perhaps low single digits or flat) after FY2025 as the initial rapid expansion fades. International ventures might underwhelm (e.g. difficulty gaining traction in crowded markets, or regulatory hurdles abroad), leaving Biome largely confined to Australia/New Zealand. In this scenario, annual revenue might only reach ~$20–25M by FY2030, far below guidance expectations. Profitability would remain marginal; the company might oscillate around breakeven or even slip back into small losses if costs rise or if heavy promotional effort is needed to drive sales. Additionally, a low-case could include external setbacks – for example, a supply chain disruption increasing costs, or a need to cut prices to stimulate demand, compressing margins. With growth disappointing, market sentiment would turn negative and the stock could de-rate significantly. We assume a P/E is not meaningful here (due to negligible earnings), and the market might value Biome on a low revenue multiple given stalled growth (perhaps ~1x sales or a small premium for its brand/IP). The 5-year share price could fall to around $0.30 or even lower in this bearish scenario (a decline of ~35–40% from today). A possible trajectory might see the stock drift down or remain volatile in a range before settling lower:

Factors: Slowing sales (e.g. <10% CAGR), loss of momentum in pharmacies, and possible capital raise or cash burn that worries investors. In a low-case, Biome’s growth story would be essentially broken, and the stock might trade like a small stagnant healthcare company. Probability Weight: 20%. (Summary: Growth Stalls*)*

Probability-Weighted Outcome: Combining these scenarios and weights, our 5-year probability-weighted target price for BIO is around $0.78. This implies a healthy upside from the current ~$0.47, driven largely by the base-case expectation of continued growth. The skew of outcomes is moderately positive, as even the base case envisions solid gains. Investors should note the risk/reward: while downside to ~$0.30 is possible in a bear case, the bull case offers multi-bagger potential. Given Biome’s track record to date and strategic plan, the base case of steady execution appears most likely. Overall, our 5-year outlook is tilted toward upside potential. 【Probability-weighted Price ≈ $0.78】 Upside Bias (expected trajectory skewed favorably).

6. Qualitative Scorecard:

We evaluate Biome on several qualitative factors (scale 1–10, with 10 being best-in-class):

• Management Alignment – 9/10: Insider ownership is high (insiders hold ~44% of shares)finance.yahoo.com, indicating skin in the game. The founder-led management has thus far executed well, exceeding targetscanarycapital.com.au. The strong insider stake and a clear strategic vision (Vision 27 plan) suggest management’s interests are closely aligned with shareholder value creation.

• Revenue Quality – 7/10: Biome’s revenue is growing rapidly and is backed by repeat consumer demand for health products. The company benefits from a diversified customer base across thousands of pharmacies and practitioners (no single customer dominates sales). Recurring purchase behavior (e.g. monthly supplements) provides some revenue stability. However, revenue quality is somewhat tempered by the fact that sales are not subscription-based and depend on continuous consumer discretionary spend and channel sell-through. As the products are premium priced, maintaining growth may require ongoing education and marketing.

• Market Position – 7/10: Within its niche, Biome has established a strong brand presence – Activated Probiotics is the fastest-growing brand in pharmacy probioticscanarycapital.com.au and has earned industry accoladesinvestorpa.com. The company has secured partnerships with major pharmacy chains, giving it shelf space and visibility. Still, Biome is a relatively small player in the global vitamins/supplements market, facing larger competitors. Its market share in Australia’s complementary medicine segment is growing but remains modest in absolute terms. Continued innovation and marketing will be needed to defend and expand its position.

• Growth Outlook – 9/10: The growth prospects are robust. Biome achieved ~80% sales growth in FY2024canarycapital.com.au and ~47% in 1H FY2025canarycapital.com.au. Its three-year plan targets over 400% growth (FY25–27 vs prior three years)canarycapital.com.au, and recent quarterly updates (40%+ growth) suggest momentum is intactinvestorpa.com. New products and international markets provide additional growth levers. While such hyper-growth will inevitably taper as the revenue base expands, Biome’s outlook remains very strong relative to peers. This score reflects the high growth trajectory, albeit recognizing that sustaining >50% CAGR is challenging long-term.

• Financial Health – 7/10: Biome’s financial health is sound for a small growth company. It has become cashflow positive and carries a cash buffer (~A$2.9M at FY24)canarycapital.com.au with minimal (if any) debt. With its first net profit just achievedcanarycapital.com.au, internal funding capacity is improving. The current ratio and working capital appear adequate, and an unrecognized tax asset will shield future earningscanarycapital.com.au. However, the company’s absolute cash reserves are not large, and it may need to reinvest heavily for growth (potentially requiring external funding if growth outpaces cash generation). Thus, while there are no signs of distress, Biome is not yet at a self-sustaining scale to merit a higher score.

• Business Viability – 8/10: The underlying business model – developing and selling clinically-backed health products – is fundamentally viable and addresses a growing consumer need. Biome has proven it can scale sales quickly and carve out a profitable niche. Its products target chronic health issues, implying persistent demand. The company’s strategy of combining scientific validation with consumer-friendly distribution gives it durability. Risks to viability would include a significant change in medical consensus around probiotics or a superior technology emerging, but given the broad applications of microbiome health, Biome’s business concept appears solid for the foreseeable future.

• Capital Allocation – 7/10: Management has been disciplined in capital use so far. IPO funds were deployed to expand distribution and product development, yielding clear revenue growth. Operating expenses have been kept in check enough to reach EBITDA positivity on rising salescanarycapital.com.au. Biome has not over-raised or excessively diluted shareholders (shares on issue rose only modestly ~8% in the past year) and seems to favor organic growth. Going forward, how management allocates cash towards R&D vs. marketing vs. possible acquisitions will be important. So far, capital allocation gets good marks, with the caveat that the company is still young and has not had to make difficult trade-off decisions (such as returning capital vs. investing, since all cash is being reinvested for growth).

• Analyst/Investor Sentiment – 6/10: Being a micro-cap, Biome has limited analyst coverage (no major broker coverage yet)marketindex.com.au. However, within small-cap investor circles, sentiment has improved alongside the company’s performance. The stock price is up ~46% year-on-yearfinance.yahoo.com and has shown strong momentum at times, suggesting optimistic investor sentiment. That said, the volatility (52-week range $0.32–$0.87finance.yahoo.com) indicates sentiment can swing widely. On forums and small-cap news sites, Biome is often highlighted positively for its growth, but the broader market is still getting to know the story. Overall sentiment is cautiously positive, but not yet at a euphoric or widely-recognized level – leaving room for sentiment to improve as the company proves itself.

• Profitability – 5/10: This is a mixed aspect at present. On one hand, Biome’s gross profit margin of ~60% is strongcanarycapital.com.au, reflecting a high-value product. On the other hand, bottom-line profitability has only just been reached on a half-year basis (net margin ~1% in 1H FY25). Biome is essentially at breakeven, with trailing net losses and very slim earnings so far. We expect profitability to improve markedly in coming years as revenue scales (the company could potentially reach mid-to-high single digit net margins in a couple of years). But until it demonstrates consistent annual profits and meaningful ROE, we score profitability as average.

• Track Record – 8/10: In its short history as a listed company (since late 2021), Biome has built an impressive track record of execution. The company has consistently delivered rapid revenue growth (exceeding its own forecastssmallcaps.com.ausmallcaps.com.au) and achieved key milestones like positive cash flow and first profit earlier than many expected. Management’s Vision 27 strategic targets appear ambitious, but the fact that Biome beat its prior cumulative revenue goal by 14%canarycapital.com.au bolsters confidence. While the public track record is only ~3 years, it has been characterized by outperformance. The one blemish was the IPO itself (the stock dipped on debut amid broader market volatility)fool.com.au, but since then, patient investors have seen substantial gains. Given the small sample size, we don’t award the highest score, but acknowledge the execution excellence to date.

Blended Score: Averaging across these factors, Biome scores roughly 7/10 on our qualitative scorecard – indicating an overall above-average quality for a growth-stage company. The business benefits from strong management alignment, a compelling growth outlook, and a sound model, tempered by the typical profitability and size risks of an early-stage venture. Overall: Above Average.

7. Conclusion & Investment Thesis:

Investment Thesis: Biome Australia presents a compelling growth story in the wellness sector, underpinned by the rising global focus on gut health. The company has quickly evolved from start-up to a profitable, ~$100M market cap enterprise by leveraging its unique evidence-based probiotics approach. Its core thesis is that increasing scientific validation of the microbiome will drive demand for targeted probiotic solutions – and Biome is positioning itself as a leader in this niche. The investment case rests on Biome’s ability to continue its rapid expansion (both geographically and through new products) while achieving economies of scale that boost profitability. If management executes the Vision 27 plan (and early results are encouragingcanarycapital.com.aucanarycapital.com.au), Biome could significantly increase its earnings power and potentially attract a higher valuation or strategic interest from larger health companies.

Key Catalysts: Over the next 1-2 years, several catalysts could unlock value: (1) Continued earnings outperformance – e.g. delivering another record result in FY2025 (the company is on track to exceed its FY24 numbers handily) and providing upbeat guidance for FY2026 would reinforce investor confidence. (2) New market entries or partnerships – for instance, a distribution deal in a large market like the US or China, or deeper penetration in Europe, would dramatically expand Biome’s addressable market. (3) Product innovation – successful launch of the new Activated Therapeutics line or breakthrough clinical results for Biome’s proprietary strains (such as BMB18) could differentiate the company and open new revenue streams. (4) Strategic moves – any M&A activity, whether Biome acquiring a complementary product line or a larger player taking a stake in Biome, could rapidly re-rate the stock. Additionally, as the company matures, initiation of coverage by analysts or uplisting to larger indices could broaden investor exposure.

Key Risks: Offsetting these positives are the risks discussed earlier – chiefly, execution risk and competition. Any signs of growth deceleration or inability to convert expansion efforts into sales (for example, if a new market launch underperforms) would likely hurt the stock given its growth premium. Margin pressures (due to cost inflation or the need for heavier marketing spend) could also weigh on profits. There is also regulatory and scientific risk: the supplement industry can be impacted by regulatory changes, and while Biome’s scientific approach is a strength, new research could always emerge that changes best practices for microbiome health. Investors should monitor quarterly cash burn or raise needs; while current performance reduces this concern, rapid expansion might necessitate fresh capital if internal cash generation lags investment needs.

Overall Outlook: In balancing the thesis, we see Biome as a high-growth, moderately high-risk investment with an attractive runway. The company’s strong execution and tailwinds in the gut-health space tilt the outlook favorably, but prudent investors will size positions appropriate to the risk (as with any small-cap). If Biome continues to deliver 40%+ growth and scales profitability, it has the potential to graduate from micro-cap status and yield substantial returns. Conversely, under a more pessimistic scenario, returns could falter; thus, the stock may be best suited for growth-oriented investors with some risk tolerance. In conclusion, Biome Australia embodies a “growth-at-a-reasonable-price” story in the health supplement sector, with significant upside if it can maintain momentum. Investment Thesis Summary: High Potential.

8. Technical Analysis, Price Action & Short-Term Outlook:

Price Action: Biome’s stock has exhibited volatility reflecting its small-cap, high-growth nature. Over the past 12 months, the share price ranged from about A$0.32 to A$0.87, rallying strongly in late 2024 and then correcting in 2025finance.yahoo.com. The surge to the 52-week high (~$0.87) came as the company repeatedly upgraded forecasts and delivered record results, prompting significant buying interest. Subsequent profit-taking and broader market softness saw the stock pull back to the mid-$0.40s by mid-2025. At roughly $0.46–0.47 todayintelligentinvestor.com.au, BIO is in a consolidation phase, holding above its year-ago levels but below its peak.

Technical Trends: From a chart perspective, the long-term trend has flattened in recent months. The stock is currently trading below its 200-day moving average (which is around A$0.58)nz.finance.yahoo.com, indicating that the strong uptrend from 2024 has transitioned into a sideways or slight downtrend in 2025. The 50-day moving average ($0.45–0.46) is now near the current pricenz.finance.yahoo.com, suggesting the stock is oscillating around its short-term mean as it tries to establish a new direction. Momentum indicators had cooled off after the pullback, though daily trading volumes remain relatively healthy (3-month average ~241k shares)finance.yahoo.com for a microcap, showing continued investor interest. Key support appears to lie around the mid-$0.40s (the recent lows around $0.45), with stronger support perhaps at $0.32 (last year’s low). On the upside, the $0.60 level (coinciding with the 200-day MA) may act as an initial resistance, and beyond that, the mid-$0.80s from the prior peak would be a major resistance level.

Short-Term Outlook: In the near term, Biome’s stock will likely be driven by news flow and market sentiment towards small-cap growth stocks. The next catalysts to watch are the company’s quarterly cashflow report and any trading updates – for example, confirmation of continued profitability and growth in Q4 FY2025 could boost confidence. Recent news has been positive: Biome reported a strong Q3 FY25 with 41% sales growth and even won a top industry awardinvestorpa.cominvestorpa.com, but the share price reaction has been muted, suggesting that investors may be awaiting the full-year results or merely digesting prior gains. Technically, if the stock can hold above $0.45 and break back above ~$0.58 (the long-term average), it would signal a bullish trend reversal and potentially attract momentum traders. Conversely, a break below ~$0.45 on high volume could signal further downside, possibly re-testing the $0.35–0.40 zone. Given the fundamentally strong trajectory, our short-term stance leans cautiously optimistic: the stock may trade range-bound in the $0.45–$0.60 band until the next earnings catalyst, but the bias is to the upside if growth data remain robust. Traders should note the relatively higher beta (around 1.2)finance.yahoo.com – the stock can move more sharply than the market on both good and bad news. Overall, in the coming months we expect gradual upward drift as buying interest returns on the back of continued good news, albeit within a volatile trading range. Short-Term Summary: Consolidating.